REPROSENT Information

Oncology has sequenced genomes, built AI on claims data, and mapped tumor biology in extraordinary detail. But no one has captured how patients actually experience therapy between visits. REPROSENT embeds directly in clinical programs to capture that signal in real time. Every cohort builds a proprietary dataset that cannot be reconstructed retroactively - and compounds with every program added. ADCs, oral KRAS inhibitors, combination regimens - all hitting the same tolerability wall. The infrastructure to understand it is being built now. Backed by Y Combinator, Harvard, Hustle Fund, and Bond. Astellas Oncology C3 Grand Prize Winner.